INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 413m ago
HOUSE PTR13m ago
SEC 13F12m ago
ROBINHOOD CHAIN12m ago
Public company

SGMOSANGAMO THERAPEUTICS, INC

CIK 0001001233

EDGAR filingsOpen in network
Disclosed transactions25
Buys / sells0 / 2
Max Insider Score41
Connections7with evidence

SGMO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$703
4,036 sh
May 25, 2026May 27, 2026
traded May 25, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Macrae SandyDirector, PRESIDENT, CEO AND DIRECTOR · Jan 26, 2026
  • ← Insider ofevidence
    Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY · Nov 26, 2025
  • ← Insider ofevidence
    Davis Gregory DHead of Research & Technology · Nov 26, 2025
9
WB
Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F
$703
4,036 sh
May 25, 2026
May 27, 2026
traded May 25, 2026
+2d
SEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$334
1,919 sh
May 25, 2026May 27, 2026
traded May 25, 2026
+2dSEC FORM 4

Evidence

5
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$284
1,630 sh
May 25, 2026May 27, 2026
traded May 25, 2026
+2dSEC FORM 4

Evidence

41
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Open-market sale
SELL$89K
345.9K sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

34
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Open-market sale
SELL$18K
69.8K sh
Apr 22, 2026Apr 23, 2026
traded Apr 22, 2026
+1dSEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Grant or award
A—
225.0K sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC FORM 4

Evidence

9
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Grant or award
A—
225.0K sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$2,406
5,119 sh
Feb 25, 2026Feb 26, 2026
traded Feb 25, 2026
+1dSEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$5,806
12.4K sh
Feb 25, 2026Feb 26, 2026
traded Feb 25, 2026
+1dSEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$975
2,063 sh
Feb 24, 2026Feb 26, 2026
traded Feb 24, 2026
+2dSEC FORM 4

Evidence

9
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$2,406
5,119 sh
Feb 25, 2026Feb 26, 2026
traded Feb 25, 2026
+1dSEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$315
666 sh
Feb 24, 2026Feb 26, 2026
traded Feb 24, 2026
+2dSEC FORM 4

Evidence

9
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$393
832 sh
Feb 24, 2026Feb 26, 2026
traded Feb 24, 2026
+2dSEC FORM 4

Evidence

13
MS
Macrae SandyDirector, PRESIDENT, CEO AND DIRECTOR
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$41K
103.0K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$3,077
7,721 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

9
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$3,077
7,721 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

13
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$15K
36.7K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

13
WB
Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$15K
36.7K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

13
DP
Duraibabu PrathyushaPRINCIPAL FINANCIAL OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$15K
36.7K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

9
WB
Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$848
2,035 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$1,060
2,544 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

9
DD
Davis Gregory DHead of Research & Technology
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$301
723 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

9
DP
Duraibabu PrathyushaPRINCIPAL FINANCIAL OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$1,060
2,544 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

9
JN
Jain NikunjPrincipal Accounting Officer
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$241
578 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER · Nov 26, 2025
  • ← Insider ofevidence
    Jain NikunjPrincipal Accounting Officer · Nov 26, 2025
  • ← Insider ofevidence
    Duraibabu PrathyushaPRINCIPAL FINANCIAL OFFICER · Nov 26, 2025
    • Source error

    Price history for SGMO is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.